Sequence driven interaction of amino acids in de-novo designed peptides determines c-Myc G-quadruplex unfolding inducing apoptosis in cancer cells

c-MYC proto-oncogene harbors a putative G-quadruplex structure (Pu27) at the NHEIII1 domain, which can shuffle between transcriptional inhibitor quadruplex and transcriptionally active duplex. In cancer cells this quadruplex destabilization is preferred and NHEIII1 domain assume a duplex topology th...

Full description

Saved in:
Bibliographic Details
Published inBiochimica et biophysica acta. General subjects Vol. 1867; no. 2; p. 130267
Main Authors Banerjee, Nilanjan, Chatterjee, Oishika, Roychowdhury, Tanaya, Basu, Debadrita, Dutta, Anindya, Chowdhury, Madhurima, Dastidar, Shubhra Ghosh, Chatterjee, Subhrangsu
Format Journal Article
LanguageEnglish
Published Netherlands Elsevier B.V 01.02.2023
Subjects
Online AccessGet full text
ISSN0304-4165
1872-8006
1872-8006
DOI10.1016/j.bbagen.2022.130267

Cover

More Information
Summary:c-MYC proto-oncogene harbors a putative G-quadruplex structure (Pu27) at the NHEIII1 domain, which can shuffle between transcriptional inhibitor quadruplex and transcriptionally active duplex. In cancer cells this quadruplex destabilization is preferred and NHEIII1 domain assume a duplex topology thereby inducing c-MYC overexpression and tumorigenesis. Hence, the c-MYC quadruplex acts as an excellent target for anti-cancer therapy. Though researcher have tried to develop G-quadruplex targeted small molecules, work with G-quadruplex targeting peptides is very limited. Here we present a peptide that can bind to c-MYC quadruplex, destabilize the tetrad core, and permit the formation of a substantially different structure from the quartet core seen in the canonical G-quadruplexes. Such conformation potentially acted as a roadblock for transcription factors thereby reducing cMYC expression. This event sensitizes the cancer cell to activate apoptotic cascade via the c-MYC-VEGF-A-BCL2 axis. This study provides a detailed insight into the peptide-quadruplex interface that encourages better pharmacophore design to target dynamic quadruplex structure. We believe that our results will contribute to the development, characterization, and optimization of G-quadruplex binding peptides for potential clinical application. Schematic representation of the mode of action of CD23 peptide. [Display omitted] •Peptides act as an excellent ligands to arrest G-quadruplex structures. Its high specificity is coupled with low toxicity•c-Myc G-quadruplex targeted therapy can be manipulated to develop gene directed anticancer therapeutics.•G-quadruplex destabilization can be exploited to develop anticancer therapy.•There is no drug targeting c-Myc oncogene. NHE-III1 element has been shown to be a fantastic target for c-Myc suppression.
Bibliography:ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 23
ISSN:0304-4165
1872-8006
1872-8006
DOI:10.1016/j.bbagen.2022.130267